NASDAQ: BOLTBolt Biotherapeutics Inc Stock
$0.36+0.01 (+2.86%)
Updated Apr 30, 2025
BOLT Price
$0.36
Fair Value Price
N/A
Market Cap
$13.61M
52 Week Low
$0.30
52 Week High
$1.34
P/E
-0.22x
P/B
0.24x
P/S
2.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.69M
Earnings
-$63.12M
Gross Margin
100%
Operating Margin
-820.78%
Profit Margin
-820.8%
Debt to Equity
0.74
Operating Cash Flow
-$61M
Beta
0.87
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BOLT Overview
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company developing immuno-oncology agents to target tumor cells for elimination by the immune system.BDC-1001, a human epidermal growth factor receptor 2 (HER2), is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors. BDC-2034 is a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. BDC-3042 is a Dectin-2 agonist antibody program intended to repolarize critical cells in the tumor microenvironment. Bolt Biotherapeutics was incorporated in 2015 and is headquartered in Redwood City, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BOLT's potential to beat the market
- BOLT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BOLT
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important BOLT news, forecast changes, insider trades & much more!
BOLT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BOLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BOLT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BOLT is good value based on its book value relative to its share price (0.24x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
BOLT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BOLT due diligence checks available for Premium users.
Valuation
BOLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
-162.28x
Market
29.18x
BOLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.24x
Industry
4.45x
BOLT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BOLT's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.9M
Profit Margin
0%
BOLT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BOLT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$99.6M
Liabilities
$42.4M
Debt to equity
0.74
BOLT's short-term assets ($50.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BOLT's short-term assets ($50.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BOLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BOLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.4M
Investing
$12.2M
Financing
$29.0k
BOLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BOLT vs Biotech Stocks
Bolt Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.